The HDAC4 Knockout 769-P Polyclonal Cells consist of a population of human 769-P renal carcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the HDAC4 gene. This polyclonal knockout cell pool provides a heterogeneous loss-of-function model for investigating HDAC4-dependent regulatory mechanisms. The use of CRISPR/Cas9 technology enables efficient editing, and the polyclonal format offers a representative genetic ablation of target gene function, avoiding clonal selection biases while maintaining biological complexity.
The host cell line, 769-P, is an established human renal cell carcinoma line derived from a primary clear cell renal adenocarcinoma of a 63-year-old female patient. This epithelial tumor cell line is widely employed as an in vitro model of clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer. It retains characteristic features of the disease, including dysregulated hypoxia signaling and altered metabolic programs, making it a relevant platform for studying ccRCC biology and therapeutic responses.
HDAC4 is a class IIa histone deacetylase that represses transcription through deacetylation of histone tails, particularly histones H3 and H4. Its activity and subcellular localization are governed by multiple upstream regulators such as CaMK kinases, PKD, and AMPK, which phosphorylate HDAC4, facilitating 14-3-3 protein binding and nuclear export via exportin CRM1. In the nucleus, HDAC4 interacts with MEF2 transcription factors (MEF2A/C/D), as well as corepressors N-CoR and SMRT, to silence MEF2-dependent genes, including those involved in muscle differentiation and tumor suppression like NR4A1 and p21. It also integrates signals from TGF-beta/BMP, p53, and Wnt pathways, and its sumoylation further modulates its repressor function.
In the context of 769-P renal carcinoma cells, HDAC4 knockout eliminates its deacetylase activity, leading to increased histone H3/H4 acetylation and derepression of MEF2 target genes and growth-suppressive genes such as p21. This molecular shift is expected to impair cell proliferation and enhance sensitivity to apoptotic stimuli, thereby reducing tumorigenic potential. Given the importance of HDAC4 in cellular survival and differentiation, this knockout model provides a valuable tool to dissect its tumor-suppressive or oncogenic roles in ccRCC and to evaluate the consequences of HDAC4 loss on tumor cell behavior.
Researchers can utilize this polyclonal knockout cell population to explore epigenetic regulation in renal cancer, validate HDAC4 as a therapeutic target for HDAC inhibitors, and investigate MEF2-dependent transcriptional programs in tumor progression. Representative assays include western blotting for acetylated histones H3 and H4, RT-qPCR for MEF2 target gene expression, MTT or BrdU proliferation assays, immunofluorescence to monitor HDAC4 localization, ChIP-qPCR for histone acetylation at specific promoters, and apoptosis detection via Annexin V staining, as well as migration, invasion, and colony formation assays. These applications support mechanistic studies and drug screening. For detailed protocols, validation data, or ordering inquiries, please contact Ascent Research.
